Causes of acute right ventricular failure in intensive care units
Right ventricular volume overload may be due to pulmonary or tricuspid regurgitation, left-to-right shunt, or anomalous pulmonary venous return. [6] Right ventricular pressure overload may be due to endothelial dysfunction, vasoconstriction, mechanical obstruction, acute respiratory distress syndrome (ARDS), massive pulmonary embolism (PE), chronic pulmonary arterial hypertension (PAH), postcardiac surgery, and mechanical ventilation. [6] Right ventricular contractile dysfunction may be due to right ventricular myocardial infarction (RVMI), right ventricular cardiomyopathy, sepsis (cytokine-induced myocardial depression), postcardiopulmonary bypass, myocarditis, pericardial disease such as constrictive pericarditis, tamponade, and left ventricular assist device (acute unloading of LV). [6] Left ventricular dysfunction caused due to myocardial ischemia and LV dilatation lead to restricted RV diastolic function. [6] Clinical features of right ventricular failure Clinical features of right ventricular failure (RVF) in the general population are mainly due to fluid retention or venous congestion seen as raised jugular venous pulse, epigastric discomfort, enlarged tender liver, ascites, and peripheral edema. The low cardiac output manifests as dyspnea on exertion, easy fatigability, and dizziness. The patient may also have atrial or ventricular tachycardia (gallop rhythm). Some of these clinical features are difficult to imply toward RVF unless there is a high level of suspicion, especially in a sedated and ventilated patient in the Intensive Care Unit (ICU).
Clinical features of right ventricular failure in mechanically ventilated patients
The cardinal signs of right ventricular failure (RVF) are increasing oxygen requirement and sudden cardiovascular collapse. [7] The other signs include atrial or ventricular arrhythmias, raised jugular venous pulse, gallop rhythm at left sternal edge, pansystolic murmur of tricuspid regurgitation, hepatomegaly, and persistent/ recurrent failure in weaning from ventilator. [8] A high index of suspicion of RVF must be maintained in patients with a past history of pulmonary artery hypertension or recent deep vein thrombosis. [9] Diagnostic tools 1. A chest X-ray will show enlarged pulmonary artery and regional oligemia in massive PE. It also helps to rule out atelectasis, pleural effusion, pulmonary edema, and pneumothorax 2. Electrocardiography may show features suggestive of right ventricular hypertrophy such as right-axis deviation, dominant R in V1, dominant S in V5, and P pulmonale. They may also show features suggestive of right ventricular myocardial infarct such as elevated ST in V 3 R and V 4 R, RV strain as evidenced by T inversion in V1 to V4, and S1Q3T3. RV dysfunction may manifest with a Qr in V1 (highly associated with troponin leakage and myocardial shear stress) [10] 3. Arterial blood gas analysis -Acidemia with lactic acidosis due to hypoperfusion and low cardiac output 4. Dynamic hemodynamic parameters -Pulse pressure variation (PPV), stroke volume variation (SVV), and cardiac output can be derived from arterial pulse contour analysis in mechanically ventilated patients. A lack of response to fluid challenge in high PPV and SVV indicates toward RV dysfunction [11] 5. Echocardiography -Transthoracic echo (TTE) and transesophageal echo (TEE) are bedside diagnostic tools for rapid diagnosis of right ventricular dysfunction/failure and help in therapeutic strategies. TTE is easy and noninvasive but gives inadequate imaging window in patients on mechanical ventilation with positive end-expiratory pressure (PEEP). TEE is semi-invasive and provides a better assessment of RV size, shape, and function.
Echocardiographic parameters indicative of RVF are as follows: [12, 13] a. Tricuspid annular plane systolic excursion (TAPSE) -It is a simple and reproducible parameter assessed by measuring longitudinal displacement of RV base toward RV apex in systole. TAPSE <16 mm indicates RV dysfunction b. Dilated RV >32 mm at base, >35 mm at mid-level, and >86 mm longitudinally c. Right ventricular outflow tract diameter >27 mm at end diastole d. RV/LV basal diameter -ratio >1 e. Loss of normal spherical shape of LV -"D" sign indicates high pulmonary artery (PA) pressures f. Inferior vena cava diameter >20 mm and loss of collapsibility indicate high right atrial pressure.
In mechanically ventilated patients, the measurement of right atrial and the PA pressure can be inaccurate due to PPV. Thus, pulmonary artery catheterization provides reliable measurement of pulmonary hemodynamics and information of RV and LV filling pressure with cardiac output. [14] Other imaging modalities
Computed tomography pulmonary angiogram -This is a diagnostic tool in suspected PE. It has 50%-100% of sensitivity and 81%-100% of specificity. [15] Signs of suspected RV dysfunction due to PE include flattening of IVS toward LV, reflux of contrast in inferior vena cava, and the RV/LV diameter >1.
Cardiovascular magnetic resonance (CMR) imaging -CMR is the gold standard and most sensitive for the assessment of RV size and function as it is not influenced by acoustic window or preexisting cardiopulmonary disease. [16] However, CMR has limitations in a critically ill patient on mechanical ventilation, due to risk during transportation and prolonged duration for magnetic resonance imaging.
Right heart catheterization can be done for the diagnosis of PAH. This method can be a constraint in critically ill patients on mechanical ventilation because of risks during transportation.
Biochemical markers
Raised B-type natriuretic peptide, troponin, and D dimer though nonspecific indicate myocardial stress and injury in RV failure scenarios. Plasma lactate levels >2 mmol/L indicate tissue hypoperfusion and these patients are at a high risk of morbidity and mortality. Liver enzymes, bilirubin, and serum creatinine may be raised in RV failure as a result of inadequate perfusion or venous congestion in RV overload.
management StrategIeS
The broad physiological principles of management of RV failure in a critically ill patient on ventilator are optimization of RV preload, optimization of RV afterload, and contractility.
Optimization of RV preload
Optimization of intravascular fluid is very important for successful management of RV failure. In critically ill patients, the intravascular fluid status may be inadequate due to increased permeability and insensible fluid loss.
Sedatives can cause decreased venous tone and reduced venous return. Mechanical ventilation increases intrathoracic pressure and reduces RV preload. Based on Frank Starling law, increase in RV preload may improve RV ejection fraction, but this may not be true in all situations.
If RV failure occurs with a normal RV afterload (normal pulmonary vascular resistance [PVR]) as in RVMI, rapid volume resuscitation is necessary to maintain adequate cardiac output, but if RV failure occurs with an increased RV afterload as in acute PE, volume overload can cause IVS displacement toward LV and decreased LV filling, simultaneously RV distension increases free wall tension, increased oxygen demand, reduced RV perfusion, and further RV ischemia. [14] A central venous line can provide central venous pressure and superior vena cava saturation (S V O 2 ) to assess right-sided filling pressures. Normal S V O 2 is 70%-80%, and lower values suggest low cardiac output.
Marik and Cavallazzi in a recent meta-analysis showed that there is not enough data to support CVP as a guide for fluid assessment and therapy. [17] Pulmonary artery catheterization and TTE/TEE are more reliable tools to guide fluid therapy. [18] In RV volume overload leading to acute kidney injury (cardiorenal syndrome), continuous venovenous hemofiltration is advisable to achieve better clinical improvement than aggressive diuretic therapy in heart failure patients. [19] 
Optimization of RV afterload
Excessive RV afterload is an important factor in most cases of acute RV failure, in critically ill patients. Efforts need to focus on reducing the afterload with pulmonary vasodilators and prompt correction of the factors that increase PVR such as hypoxemia, hypercapnia, and acidosis. SpO 2 needs to be kept above 92% with PCO 2 , pH near-normal values, and ventilator setting to achieve a lung volume near functional residual capacity (FRC).
Pulmonary vasodilators
The role of pulmonary vasodilators in acute RV failure is to decrease PVR, improve RV stroke volume and RV output, and avoid systemic hypotension and maintain coronary perfusion.
Several classes of pulmonary vasodilators are developed over the last two decades for PAH.
Inhaled nitric oxide
A potent pulmonary vasodilator acts by increasing intracellular cyclic guanosine monophosphate (cGMP) and has a rapid onset and short half-life. It improves PaO 2 /FiO 2 ratio and cardiac output in ventilated patients with acute RV failure due to ARDS. [20] It can be an ideal agent to rapidly reduce RV afterload for a short-term therapy.
Rossaint et al. have shown that it improves RV ejection fraction and RV end-diastolic volume in patients with RV failure due to severe ARDS. [21] Bhorade et al. have shown that it improves pulmonary hemodynamics and mixed venous SpO 2 in acute RV failure. [22] Prostacyclin derivatives
They are potent pulmonary vasodilators with rapid onset and short half-life and hence, the initial therapy of choice in severe PAH with RV failure. They act by increasing intracellular cyclic adenosine monophosphate (cAMP) levels and may also have inotropic action. At present, three prostacyclin derivatives are available: epoprostenol, treprostinil, and iloprost.
Radermacher et al. showed that intravenous (IV) epoprostenol reduces PVR and improves RV function in patients with ARDS on mechanical ventilation. [23] Muzaffar et al. have used inhaled epoprostenol to successfully manage patients with RV failure in postcardiac surgery patients. [24] Epoprostenol and iloprost are potent pulmonary and systemic vasodilators with antithrombotic and antiproliferative actions. They reduce PVR and improve RV function in acute RV failure. All the three drugs can be used by inhalational therapy to avoid systemic hypotension.
Phosphodiesterase 5 inhibitors
These agents inhibit the metabolism of cGMP and potentiate the beneficial effect of nitric oxide. Oral preparations must be used carefully as they cause systemic vasodilation and have longer half-life.
Oral sildenafil and tadalafil reduce PVR, improve myocardial perfusion, and may improve RV contractility. [25] Intravenous preparation of sildenafil with shorter half-life is available and can be useful in RV failure in ICU patients on mechanical ventilation. [26] Other pulmonary vasodilators such as endothelin receptor antagonist (ambrisentan and bosentan) and soluble guanylate cyclase stimulator (Riociguat) are not tried and tested in acute RV failure.
Optimization of RV contractility
The RV contractility is reduced in acute RV failure due to overstretching of RV free wall, derangement in cellular metabolism, and inadequate coronary perfusion, leading to insufficient oxygen delivery. Increase in RV preload or afterload increases the RV free wall tension and oxygen demand and simultaneously reduces LV filling, LV output, and coronary perfusion. Metabolic derangement due to acid-base imbalance, oxygen-free radicals, and cytokines can cause RV failure in critically ill patients. [27] In patients of acute RV failure with chronic pulmonary vascular disease, the RV systolic pressure may be near systemic pressure. Hence, the primary goal should be to keep systemic blood pressure above RV systolic pressure and thus, the role of vasopressors is very important here.
Vasopressors
An ideal agent would be the one which increases the systemic vascular resistance and systemic blood pressure without raising PVR and improves RV contractility. Norepinephrine principally acts on α 1 receptors and causes vasoconstriction with limited β 1 stimulation and cardiac inotropy. Phenylephrine is purely an α 1 agonist, causes vasoconstriction and improves coronary perfusion but it may also increase the PVR. Vasopressin at lower doses (0.01-0.03 U/min) causes pulmonary vasodilatation and at higher doses causes pulmonary and systemic vasoconstriction. Epinephrine is a mixed αand β-receptor agonist that causes vasoconstriction and inotropy. All in all, norepinephrine is the initial agent in hypotensive patients with RV failure.
Inotropes
These are indicated in patients with acute RV failure and have a low cardiac output.
Dobutamine acts through β 1 and β 2 receptors, causes vasodilatation, and improves cardiac output at lower doses. At higher doses, it can cause tachycardia and hypotension.
Milrinone is a selective phosphodiesterase 3 inhibitor. It slows intracellular cAMP metabolism, causes pulmonary vasodilatation, and improves RV contractility. It is the drug of choice in pulmonary vascular disease with severe PAH and biventricular failure. It is preferred over dobutamine as it has less chronotropic effect.
Inotropes can cause tachycardia and should be considered only when there is evidence of inadequate oxygen delivery in spite of correction of RV preload, RV afterload, and ischemia.
Levosimendan is a calcium sensitizer. It improves myocardial contractility without increasing cytosolic calcium and oxygen demand. In patients having RV failure with chronic thromboembolic pulmonary hypertension (CTPH), levosimendan has been shown to improve RV function. [28] Maintenance of sinus rhythm and heart rate control is important for RV failure scenario.
goalS of mechanIcal ventIlatIon
The goals of mechanical ventilation are as follows: avoid hypoxia, hypercapnia, and high PEEP (10 cmH 2 O). Adopt lung protective ventilator strategy (low tidal volume, low plateau pressure, and PEEP). RV afterload is determined by PVR, which is affected by the changes in lung volume. The PVR is high, both at low as well as high lung volumes. At low volumes, PVR is high due to elastic recoil of lung parenchyma leading to extra-alveolar vessel collapse and terminal airway collapse leading to alveolar hypoxia and hypoxic pulmonary vasoconstriction. At high volumes, PVR is high because stretching of alveolar walls leads to collapse of alveolar vessels. [29] The total PVR is lowest at FRC, whereas vascular resistance in intra-and extra-alveolar vessels is intermediate.
Schmitt et al. demonstrated that high PEEP (13 cm ± 4 cmH 2 O)
is associated with increased RV afterload and worsening of RV systolic function. [30] The use of lung protective strategies (low V T 6-8 ml/kg, low plateau pressure, and low PEEP) in ARDS net trial showed a significant decrease of incidence of acute RV failure in ARDS group. [31] During lung protective strategy in acute RV failure condition, it is very important to avoid hypercapnia as it can increase PVR and worsen RV function. Hence, in these patients, it is recommended to gradually adopt lung protective ventilation strategies keeping an eye on hypercapnia and RV function. [32] It is important to remember that these patients of acute RV failure on mechanical ventilation may be difficult to wean off the ventilator, as weaning may worsen (increase) RV afterload due to increase in work of breathing, hypoxemia, or high intrinsic PEEP, which can lead to further RV enlargement and shift of IVS toward LV, affecting LV filling and LV output. This can cause pulmonary edema and thus leads to failure in weaning from mechanical ventilation. [33] 
Mechanical support
In mechanically ventilated patients with severe RV failure where the medical therapy is ineffective and patients have hypoxemia and/or hypercapnia and need high PEEP, they are the ones who may do well with mechanical circulatory support such as extra corporeal membrane oxygenation (ECMO) until the recovery of respiratory function. [34] In patients with RV failure due to ARDS, with severe intractable hypercapnic acidosis, where the ventilator therapy is ineffective, Extracorporeal Carbon dioxide removal devices like -Interventional Lung Assist (NovaLung GmbH, Hechingen, Germany), may be useful as they are pumpless and are less invasive than ECMO and ultraprotective lung protection strategy can be instituted.
(VT -4ml/kg of predicted body weight). [35] In patients with RV failure due to massive PE, chronic thromboembolic pulmonary hypertension (CTPH), and PAH, venovenous or venoarterial (VA) ECMO is used successfully as a bridge to pulmonary endarterectomy or lung transplantation. [36, 37] Mydin et al. have shown that VA ECMO improves RV function and oxygen delivery in awake spontaneously breathing patients as a bridge to pulmonary endarterectomy. [38] In patients with acute RV failure, due to primary RV pathology and RV dysfunction refractory to medical treatment, mechanical support of RV such as right ventricular assist device is used as a bridge to recovery or bridge to heart transplant. [39] Recently, pumpless lung assist devices have been developed that connect the PA to left atrium with low resistance membrane oxygenator and it has been tried in patients with PAH as a bridge to lung transplant. The low resistance circuit offloads the RV and improves LV filling. [40] Salient points in the management of acute RV failure are as follows: 
concluSIon
RV failure is seen increasingly in critically ill patients on mechanical ventilation in an ICU and carries significant morbidity and mortality. RV failure is a complex clinical syndrome, challenging to diagnose in critically ill patients, and it can be taxing for intensive care specialists. Common causes of acute RV failure are RVMI, massive PE, severe PAH, and congenital heart diseases.
It is important to diagnose RV failure early and identify and correct the reversible factors followed by optimization of RV preload, reducing the RV afterload and improving RV contractility.
When all the options of medical management are exhausted, extra corporeal life support in the form of ECMO is effective in restoring circulatory support to all vital organs and is indicated as a bridge to recovery in patients with reversible RV failure, and bridge to surgical interventions such as pulmonary endarterectomy, lung transplant, heart transplant, or heart-lung transplant.
Early referral to specialized centers should be sought in need of mechanical circulatory support. Well-designed randomized controlled trials are the need of time for better understanding of the various mechanisms of acute RV failure and guide the therapy in critically ill patients on mechanical ventilator.
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